Gemphire Therapeutics Inc (NASDAQ:GEMP) has earned an average rating of “Buy” from the six analysts that are covering the firm. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $21.80.
A number of equities research analysts have weighed in on the company. Canaccord Genuity set a $17.00 price objective on Gemphire Therapeutics and gave the company a “buy” rating in a report on Thursday, March 16th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Gemphire Therapeutics in a report on Tuesday. Zacks Investment Research lowered Gemphire Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Piper Jaffray Companies assumed coverage on Gemphire Therapeutics in a report on Monday. They issued an “overweight” rating and a $30.00 price objective on the stock.
Gemphire Therapeutics (NASDAQ:GEMP) traded up 1.30% during midday trading on Monday, hitting $11.65. The company had a trading volume of 28,732 shares. The stock’s 50-day moving average price is $10.18 and its 200-day moving average price is $9.86. The stock’s market cap is $108.02 million. Gemphire Therapeutics has a 52-week low of $7.25 and a 52-week high of $13.98.
Gemphire Therapeutics (NASDAQ:GEMP) last announced its quarterly earnings data on Wednesday, March 15th. The company reported ($0.78) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by $0.24. On average, equities research analysts expect that Gemphire Therapeutics will post ($2.24) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at http://sleekmoney.com/gemphire-therapeutics-inc-gemp-receives-21-80-consensus-pt-from-analysts/1739681.html.
In other Gemphire Therapeutics news, Director Andy Sassine acquired 21,119 shares of the stock in a transaction on Friday, March 10th. The shares were bought at an average price of $9.47 per share, with a total value of $199,996.93. Following the acquisition, the director now owns 136,264 shares of the company’s stock, valued at $1,290,420.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Large investors have recently made changes to their positions in the stock. Blue Clay Capital Management LLC acquired a new stake in shares of Gemphire Therapeutics during the third quarter worth $131,000. Monashee Investment Management LLC acquired a new stake in shares of Gemphire Therapeutics during the third quarter worth $144,000. Spark Investment Management LLC acquired a new stake in shares of Gemphire Therapeutics during the third quarter worth $198,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of Gemphire Therapeutics during the third quarter worth $3,976,000. 14.85% of the stock is currently owned by institutional investors.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/gemphire-therapeutics-inc-gemp-receives-21-80-consensus-pt-from-analysts/1739681.html
Receive News & Ratings for Gemphire Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.